| Sulanda (surufatinib) / Hutchmed |
NCT05106777: Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma |
|
|
| Recruiting | 2 | 47 | RoW | Surufatinib, HMPL-012 | Sun Yat-sen University | Sarcoma | 12/23 | 12/23 | | |
NCT06110650: A Study of Surufatinib in the Treatment of Advanced Soft Tissue Sarcoma |
|
|
| Not yet recruiting | 2 | 29 | NA | Surufatinib | Fudan University | Soft Tissue Sarcoma Adult | 08/24 | 08/25 | | |
ChiCTR2100053490: A phase 2 study of Surufatinib in patients after first line standard chemotherapy or Anlotinib treatment failure of soft tissue sarcoma |
|
|
| Recruiting | 2 | 64 | | Surufatinib+Gemcitabine ;Surufatinib | Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University, Part of self-raised, part of Hutchison Whampoa Pharmaceuticals (Shanghai) Co., Ltd. | Soft Tissue Sarcoma | | | | |
NCT05926492: A Clinical Study of Surufatinib Combined With Chemotherapy as Neoadjuvant Treatment in Osteosarcoma |
|
|
| Recruiting | 2 | 160 | RoW | Surufatinib plus chemotherapy, Arm A, Chemotherapy, Arm B | Second Affiliated Hospital, School of Medicine, Zhejiang University | Osteosarcoma | 07/25 | 07/26 | | |
ChiCTR2200062533: A single-arm, open-lab, single-center Phase II study of surufatinib combined with penpulimab in the second-line treatment of unresectable stage IIB or III osteosarcoma or soft tissue sarcoma |
|
|
| Not yet recruiting | 2 | 38 | | surufatinib combined with penpulimab | The First Affiliated Hospital, Sun Yat-Sen University; The First Affiliated Hospital, Sun Yat-Sen University, No funds | Sarcoma | | | | |
NCT05722977: Surufatinib and Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients |
|
|
| Not yet recruiting | 2 | 45 | NA | Surufatinib + envafolimab | Peking Union Medical College Hospital | Efficacy and Safety of Surufatinib Combined With Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients | 02/26 | 02/27 | | |
NCT05093322 / 2021-003602-41: A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors |
|
|
| Completed | 1/2 | 13 | US | Surufatinib in combination with Gemcitabine, HMPL-012, sulfatinib in combination with Gemcitabine | Hutchmed, HUTCHMED Limited | Solid Tumor, Lymphoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) | 04/23 | 04/23 | | |
NCT04579757: Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors |
|
|
| Active, not recruiting | 1/2 | 135 | US | Surufatinib and Tislelizumab _ Part 1, HMPL-012, sulfatinib, BGB-A317, Surufatinib and Tislelizumab _ Part 2 | Hutchmed, BeiGene | Metastatic Solid Tumor, Colorectal Cancer, Neuroendocrine Tumors, Small Cell Lung Cancer, Gastric Cancer, Soft Tissue Sarcoma, Anaplastic Thyroid Cancer | 04/24 | 06/24 | | |
IRIS, NCT05839275: The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma |
|
|
| Recruiting | 1/2 | 52 | RoW | Surufatinib, Sintilimab, Radiotherapy | Fudan University | High-Risk Localized Soft Tissue Sarcoma | 07/24 | 07/29 | | |
NCT05494580: Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer |
|
|
| Recruiting | 1/2 | 38 | RoW | Pamiparib, Poly (ADP-ribose) polymerase (PARP) inhibitor, Surufatinib, Tyrosine Kinase Inhibitor | Sun Yat-sen University, Hutchmed | Ovarian Cancer, Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Fallopian Tube Carcinosarcoma, Primary Peritoneal Cancer | 08/24 | 08/25 | | |
NCT05590572: A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma |
|
|
| Not yet recruiting | 1/2 | 148 | RoW | Sulfatinib, Etoposide, Isophosphamide | Second Affiliated Hospital, School of Medicine, Zhejiang University, Chonnam National University, Peking University People's Hospital, Qilu Hospital of Shandong University, Ruijin Hospital, Shanghai Jiao Tong University Affiliated Sixth People's Hospital | Osteosarcoma | 12/26 | 12/27 | | |
